ALPS Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

ALPS Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-24,898	Closed	-$296K	–	1076
2022 Q3	$296K	Sell	24,898 -2,142	-8%	-$30.9K	﹤0.01%	814
2022 Q2	$385K	Buy	+27,040	New	+$394K	﹤0.01%	661

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

ALPS Advisors's PMVP Position: Q4 2022 in Review

ALPS Advisors sold out of PMV Pharmaceuticals (PMVP) in Q4 2022, closing a stake of 24,898 shares — an estimated $296K sold.

ALPS Advisors first reported a position in PMVP in Q2 2022 and held it in 2 quarters. The position peaked at $385K in Q2 2022. 115 funds tracked by Wall St. Rank hold PMVP as of Q4 2022.

ALPS Advisors reported no remaining PMV Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
ALPS Advisors sold 24,898 PMV Pharmaceuticals shares in Q4 2022, an estimated $296K.
ALPS Advisors first reported a position in PMV Pharmaceuticals in Q2 2022 and held it in 2 quarters.
ALPS Advisors's PMV Pharmaceuticals position peaked at $385K in Q2 2022.
115 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.